Polarean boost as analyst repeats 'buy' rating and 4p price target

Stifel reiterated its 'buy' rating on Polarean Imaging PLC with a 4p price target, a significant premium to its current 0.46p valuation, following a supply deal with the University of Virginia Health. This agreement will equip UVA with Polarean's hyperpolarisers for converting xenon gas into an MRI imaging agent for lung function, with the first clinical scan anticipated in Q4, signaling a transition from research to clinical practice. Stifel projects this deal will support the low end of Polarean's reduced 2025 sales guidance of $2.5-$3.5 million, maintaining its forecast at $2.5 million.

Analysis

Stifel has reiterated its 'buy' rating and a 4p price target on Polarean Imaging (AIM:POLX), representing a significant premium to the current 0.46p share price. The primary catalyst for this rating is a new supply agreement with the University of Virginia (UVA) Health, which will see the installation of Polarean's clinical-grade hyperpolariser systems. This technology converts xenon gas into an imaging agent for detailed MRI scans of lung function. The deal is a critical milestone, marking the company's transition from research-use-only to clinical application, with the first patient scan at UVA anticipated in Q4 2025. The analyst note indicates this contract should support the low end of Polarean's reduced 2025 sales guidance of $2.5 million to $3.5 million, though Stifel's own forecast remains conservatively at the $2.5 million floor. The choice of UVA is significant, as it was a site for Polarean's early human trials and has secured $7.4 million in NIH funding for related respiratory studies, adding external validation to the technology's clinical potential.

Key Decisions for Investors

• The substantial gap between the current 0.46p valuation and Stifel's 4p price target, underpinned by the UVA clinical commercialization milestone, may appeal to investors with a high tolerance for risk in the micro-cap biotech sector.
• Investors should closely monitor for the successful execution of the first clinical scan at UVA in Q4, as this event is a key de-risking catalyst and proof point for the company's commercial viability.
• Given that the UVA deal is only expected to support the low end of a previously reduced sales guidance, it is prudent to watch for additional contract wins or sales data that would provide confidence in Polarean's ability to meet or exceed its full $2.5-$3.5 million forecast for 2025.